Aridis Pharmaceuticals, Inc.
ARDS evidence brief
What we can confirm
- Market Cap:
- $138K
What it means
What to watch
Prepared research question
What matters most for ARDS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
Market Cap
$138K
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 3 clinical trials for Aridis Pharmaceuticals, Inc..
Run Aridis Pharmaceuticals, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Aridis Pharmaceuticals, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 6.8%
- Days to cover
- 0.2
- Shares short
- 2,003,965
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARDS short interestGovernance
Frequently asked questions
Who is the CEO of Aridis Pharmaceuticals, Inc.?
Dr. Vu L. Truong Ph.D. is the chief executive officer of Aridis Pharmaceuticals, Inc. (ARDS).
Where is Aridis Pharmaceuticals, Inc. headquartered?
Aridis Pharmaceuticals, Inc. (ARDS) is headquartered in Los Gatos, CA, United States.
What therapeutic areas does Aridis Pharmaceuticals, Inc. focus on?
Aridis Pharmaceuticals, Inc. develops therapies across Oncology, Rare Disease, Infectious Disease, Respiratory, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.